Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DKRd in High-Risk Newly Diagnosed Multiple Myeloma
NCT06409702Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Jun 2024
- Primary completion
- Nov 2027
- Modality
- Reversible Covalent Inhibitors, Monoclonal Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of daratumumab, carfilzomib in multiple myeloma (MM), sponsored by First Affiliated Hospital of Soochow University. Started Jun 2024; status: recruiting.
02
Drugs
daratumumabcarfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06409702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06409702.